Track: CME Session
Track: Hybrid Session
Rana McKay, MD
UCSD
La Jolla, CA, United States
Disclosure(s): Contract Research: Bayer (Ongoing); Tempus (Ongoing)
Non-CE Consulting: AstraZeneca (Ongoing); Aveo (Ongoing); Bayer (Ongoing); BMS (Ongoing); Calithera (Ongoing); Caris (Ongoing); Dendreon (Ongoing); Exelixis (Ongoing); JNJ (Ongoing); Merck (Ongoing); Myovant (Ongoing); Novartis (Ongoing); Pfizer (Ongoing); Sanofi (Ongoing); Sorrento Therapeutics (Ongoing); Telix (Ongoing); Tempus (Ongoing)
Naomi Haas, MD
Penn Medicine
HAVERFORD, Pennsylvania, United States
Disclosure(s): MSD Brazilian adjuvant therapy discussion: Merck (Ongoing)
Non-CE Consulting: Aveo (Terminated, May 18, 2022); Merck (Terminated, May 18, 2022); Roche/Genentech (Terminated, May 18, 2022)
Raquib Hannan, MD, PhD
University of Texas Southwestern
Disclosure(s): No financial relationships to disclose
Bradley McGregor, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Disclosure(s): Contract Research: Aveo (Ongoing); BMS (Ongoing); Exelixis (Ongoing); Prize (Ongoing); SeaGen (Ongoing)
Non-CE Consulting: BMS (Ongoing); Eisai (Ongoing); EMD Serono (Ongoing); Exelixis (Ongoing); Merck CgA (Ongoing); Prize (Ongoing); SeaGen (Ongoing)
Rana McKay, MD
UCSD
La Jolla, CA, United States
Disclosure(s): Contract Research: Bayer (Ongoing); Tempus (Ongoing)
Non-CE Consulting: AstraZeneca (Ongoing); Aveo (Ongoing); Bayer (Ongoing); BMS (Ongoing); Calithera (Ongoing); Caris (Ongoing); Dendreon (Ongoing); Exelixis (Ongoing); JNJ (Ongoing); Merck (Ongoing); Myovant (Ongoing); Novartis (Ongoing); Pfizer (Ongoing); Sanofi (Ongoing); Sorrento Therapeutics (Ongoing); Telix (Ongoing); Tempus (Ongoing)
Yousef Zakharia, MD
University of Iowa
Disclosure(s): Advisory Board: Astra-Zeneca (Terminated); Bayer (Terminated); BMS (Terminated); Eisai (Terminated); Exelixis (Terminated); Pfizer (Terminated)
Vitaly Margulis, MD
University of Texas Southwestern
Dallas, Texas, United States
Disclosure(s): No financial relationships to disclose
Rana McKay, MD
UCSD
La Jolla, CA, United States
Disclosure(s): Contract Research: Bayer (Ongoing); Tempus (Ongoing)
Non-CE Consulting: AstraZeneca (Ongoing); Aveo (Ongoing); Bayer (Ongoing); BMS (Ongoing); Calithera (Ongoing); Caris (Ongoing); Dendreon (Ongoing); Exelixis (Ongoing); JNJ (Ongoing); Merck (Ongoing); Myovant (Ongoing); Novartis (Ongoing); Pfizer (Ongoing); Sanofi (Ongoing); Sorrento Therapeutics (Ongoing); Telix (Ongoing); Tempus (Ongoing)
Chair: Rana McKay, MD – UCSD
Speaker: Rana McKay, MD – UCSD
Debate Speaker: Phillip M. Pierorazio, MD – Penn Medicine
Debate Speaker: Raquib Hannan, MD, PhD – University of Texas Southwestern
Speaker: Vitaly Margulis, MD – University of Texas Southwestern
Debate Speaker: Bradley McGregor, MD – Dana-Farber Cancer Institute
Debate Speaker: Naomi Balzer Haas, MD – Penn Medicine
Speaker: Vitaly Margulis, MD – University of Texas Southwestern
Debate Speaker: Yousef Zakharia, MD – University of Iowa
Debate Speaker: Rana McKay, MD – UCSD
Speaker: Vitaly Margulis, MD – University of Texas Southwestern